40 phenotypes from 3 alleles in 3 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Agltm1a(EUCOMM)Wtsi/Agltm1a(EUCOMM)Wtsi involves: C57BL/6N	abnormal hepatocyte morphology	J:212003
	decreased grip strength	J:212003
	decreased locomotor activity	J:212003
	enlarged liver	J:212003
	hypoglycemia	J:212003
	increased cardiac muscle glycogen level	J:212003
	increased circulating alanine transaminase level	J:212003
	increased circulating alkaline phosphatase level	J:212003
	increased circulating aspartate transaminase level	J:212003
	increased circulating creatine kinase level	J:212003
	increased liver glycogen level	J:212003
	increased skeletal muscle glycogen level	J:212003
	liver fibrosis	J:212003
	muscle weakness	J:212003
	premature death	J:212003
Agltm1b(EUCOMM)Wtsi/Agl+ C57BL/6N-Agltm1b(EUCOMM)Wtsi/H	tremors	J:211773
Agltm1b(EUCOMM)Wtsi/Agltm1b(EUCOMM)Wtsi C57BL/6N-Agltm1b(EUCOMM)Wtsi/H	abnormal gait	J:211773
	cataract	J:211773
	decreased bone mineral content	J:211773
	decreased bone mineral density	J:211773
	decreased circulating glucose level	J:211773
	decreased total body fat amount	J:211773
	impaired glucose tolerance	J:211773
	increased circulating alanine transaminase level	J:211773
	increased circulating alkaline phosphatase level	J:211773
	increased circulating amylase level	J:211773
	increased circulating aspartate transaminase level	J:211773
	increased circulating bilirubin level	J:211773
	increased circulating cholesterol level	J:211773
	increased circulating creatine kinase level	J:211773
	increased circulating iron level	J:211773
	increased fasting circulating glucose level	J:211773
	increased heart weight	J:211773
	increased kidney weight	J:211773
	increased lean body mass	J:211773
	preweaning lethality, incomplete penetrance	J:211773
Agltm1Geno/Agltm1Geno C57BL/6J-Agltm1Geno	abnormal gait	J:218471
	abnormal hepatocyte morphology	J:218471
	abnormal liver morphology	J:218471
	decreased circulating glucose level	J:218471
	decreased fasting circulating glucose level	J:218471
	enlarged liver	J:218471
	impaired coordination	J:218471
	impaired exercise endurance	J:218471
	increased brain glycogen level	J:218471
	increased cardiac muscle glycogen level	J:218471
	increased circulating alanine transaminase level	J:218471
	increased circulating alkaline phosphatase level	J:218471
	increased circulating aspartate transaminase level	J:218471
	increased circulating creatine kinase level	J:218471
	increased glycogen level	J:218471
	increased liver glycogen level	J:218471
	increased pulmonary respiratory rate	J:218471
	increased skeletal muscle glycogen level	J:218471
	kyphosis	J:218471
	premature death	J:218471